Voyager, Neurocrine sign new deal worth up to $4.2B

Voyager Therapeutics Inc., the gene therapy startup led by erstwhile Biogen Inc. executive Al Sandrock, has a new deal with a San Diego biotech that's worth up to $4.2 billion.